| 前收市價 | 3.1600 |
| 開市 | 2.7000 |
| 買盤 | 2.9000 |
| 賣出價 | 3.3000 |
| 拍板 | 92.50 |
| 到期日 | 2024-05-17 |
| 今日波幅 | 2.7000 - 3.6600 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 539 |
ZacksWhy Earnings Season Could Be Great for BioNTech (BNTX)
BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ZacksBioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.
- Reuters
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
